Study Summary
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
Want to learn more about this trial?
Request More InfoInterventions
KYMRIAHDRUG
FDA approved CD19-directed genetically modified autologous T cell immunotherapy comprised of autologous T cells
YESCARTADRUG
CD19-directed genetically modified autologous T cell immunotherapy
Fludarabine 30mg/m2 4 dosesDRUG
30 mg/m2 IV daily for 4 doses
Cyclophosphamide 500 mg/m2; 2 dosesDRUG
500 mg/m2 IV daily for 2 doses starting with the first dose of fludarabine
Fludarabine 30mg/m2 3 dosesDRUG
30 mg/m2 IV daily for 3 doses
Cyclophosphamide 500 mg/m2; 3 dosesDRUG
500 mg/m2 IV daily for 3 doses starting with the first dose of fludarabine
Fludarabine 25mg/m2 3 daysDRUG
25 mg/m2 i.v. daily for 3 days
Cyclophosphamide 250 mg/m2; 3 daysDRUG
250 mg/m2 IV daily for 3 days starting with the first dose of fludarabine
TecartusDRUG
TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy, binds to CD19-expressing cancer cells and normal B cells
Abecma, Intravenous SuspensionDRUG
Infuse ABECMA 2 days after completion of lymphodepleting chemotherapy.
Cyclophosphamide 900 mg/m2; 1 dayDRUG
Administer cyclophosphamide 900 mg/m2 over 60 minutes on the second day before infusion of TECARTUS
Breyanzi Injectable ProductDRUG
Infuse BREYANZI 2 to 7 days after completion of lymphodepleting chemotherapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | United States |